Case 3: Relapsed Muscle-Invasive Bladder Cancer, FGFR3+

EXPERT PERSPECTIVE VIRTUAL TUMOR BOARD

Tian Zhang, MD:Our third case is a 53-year-old man who went to his primary care provider for a gross hematuria that had persisted for a week after Bactrim treatment. Cystoscopy showed a 2.8 cm bladder mass. And on transurethral resection of the bladder, tumor pathology showed a high-grade invasive urothelial cancer with invasion into the muscularis propria. His imaging studies were positive for metastatic urothelial carcinoma in the retroperitoneal lymph nodes.

He went on to receive 6 cycles of cisplatin and gemcitabine, and then achieved a partial response from his initial chemotherapy. However, after about 8 months his surveillance CT [computed tomography] scan showed disease progression, including 1 new liver lesion. And his molecular testing results we are lucky to have back. His PD-L1 [programmed death-ligand 1] IHC [immunohistochemistry] was at 0%, but hisFGFR3was positive for a mutation at S249C, and that was done by a RT-PCR [reverse transcription polymerase chain reaction] assay.

His ECOG [Eastern Cooperative Oncology Group] performance status is excellent, it’s at 1; and his estimated glomerular filtration rate is 56; he also has adequate s hematologic and hepatic parameters.

Transcript edited for clarity.